The field of radiation oncology will forever appreciate the contributions of Pat Kupelian to the field who tonight celebrated his retirement with the people who love him most. Congrats Pat! #ASTRO25
Voting for ACRO officers starts in just over one week…here is my vision for leading ACRO…
Growing up in a family of seven, I learned at an early age that it is only by speaking-up that we get our needs met. I am fortunate to have a voice that is easily heard, and today, I am asking that you let me use my voice to lead ACRO and thereby ensure that your voice is heard.
Enthusiastic advocacy for our field, and for us as radiation oncologists has characterized my record. As vice-chair of the GREC, I have used my voice to explain the value of radiation oncology in the halls of government in Washington. As ACRO's advisor to the AMA Relative Value Update Committee (RUC), I have clearly articulated the efforts we make and the value we bring, thereby helping ensure our coding and reimbursement is appropriate. As deputy-editor of ACRO's new journal, CURiE, I have fostered compelling publications that speak to the need for fairness in reimbursement. As chair of the ACROPath project, I have endeavored to design a resource clinicians can use to defend a range of appropriate, data-backed care pathways, and not just those deemed desirable by insurers and benefit managers. In each of these efforts, I have elevated your voice as an ACRO member, ensuring that nobody is drowned-out.
At times, it seems radiation oncology is under constant threat from ever tightening reimbursement structures, and from encroachment by other disciplines. We need a strong voice leading ACRO to remind those around us of the exceptional value radiation oncology brings to cancer care and beyond. If elected, I will ensure that my voice echoes yours, expressing your concerns and protecting your interests in the process.
If our voices are heard, radiation oncology will remain the most technologically exciting and personally rewarding discipline in all of medicine, even as I believe it is today. We have potential to excel beyond our imagination as we serve patients who deserve our best. But, we need a clear voice leading that charge. I ask for your vote, and I promise that if lam elected, your voice will be heard.
#YOURVOICE
#OURVOICE
#ACROVOICE
#ASTRO24: Clifford Robinson, MD, (@SBRT_CR), a Washington University Radiation Oncologist, at the @ASTRO_org Fellow induction ceremony. Congratulations!
📸w/ Dr. @lauren_henke during the awards presentation
A.J. Hinch gives a speech to ignite a chaotic Tigers locker room celebration.
That's followed by a message from Bally Sports Detroit's John Keating: "We'll apologize in advance for any language that you might hear on your cable airwaves over the course of the next hour or so."
Hey you! Yeah you, with the well run successful medical practice. You don’t need to sell to private equity! If you do…
Your staff will look for other jobs.
You and your senior partners (financial beneficiaries of PE transaction) will lose motivation forcing younger partners/associates to pick up the slack
Your younger partners/associates will resent you, but won’t be able to say anything due to power dynamics and fear of retribution from PE overlords
You’ll lose your recruiting edge
You will not practice medicine the way you want, you will practice medicine the way private equity wants
Patients will say things like “why is everybody so grumpy here?” and “what happened to this place?”
Instead, keep your practice, you’re doing great!
It is with profound sadness that I share the news of today's passing of Dr. Carlos A Perez, former Chair of Radiation Oncology at Washington University and the Mallinckrodt Institute of Radiology. @WashURadOnc @ASTRO_org
https://t.co/XftNl2A60U
It is misleading to state”no benefit“. The article concluded “A strong OS difference between CS and CRS was not identified.” in this limited post-hoc subgroup analysis but 7.8% absolute benefits was observed with chemo/RT. #radonc#esophagealcancer
Special congratulations to Dr Tom Boike for being selected as a 2023 @ASTRO_org fellow! Extraordinarily talented expert in theranostics and clinical trials , terrific physician, and amazing vertical leader!!! @GenesisCareUS @UTSW_RadOnc@NRGonc@theNCI
Randomized study published in Lancet today, showing 62% EFS improvement with Nivo + SABR compared with SABR alone in early stage NSCLC. I-SABR is a promising TX option.
awbs://authors.elsevier.com/c/1hRV5V-4XL3dJ
@IASLC@MDAndersonNews@TheLancet@ACKoongMDPhD@StephenVLiu
@ParikhSimul When I joined the ASTRO board in 2014, I was the youngest member by 9 years and only a decade out from training. I was a board outlier.
I believed Chirag Shah’s article. I brought up the issue of overtraining at my very first board meeting. It was not well received :)
1/x